知镜 Cognispect · 医学文献与研究工作台

Efficacy Heterogeneity of Hemoperfusion Plus Continuous Venovenous Hemofiltration for Hypertriglyceridemia-Induced Acute Pancreatitis Stratified by Severity of Inflammatory Response.

Li A, Zhu Q, Peng M, Lin T, Liu Z, Pan X.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026-11-08 · PMID 43000034

文献摘要

Background This study aimed to investigate the heterogeneity in the efficacy of hemoperfusion (HP) plus continuous venovenous hemofiltration (CVVH) versus CVVH alone in reducing the incidence of severe acute pancreatitis (SAP) among patients with hypertriglyceridemia-induced acute pancreatitis (HTG-AP), stratified by the inflammatory marker C-reactive protein (CRP). In addition, we assessed secondary outcomes encompassing laboratory response, disease severity and organ function, healthcare resource utilization, and treatment-related indicators, so as to delineate the broader efficacy profile of the combination therapy and its relationship with the primary endpoint. Furthermore, we sought to identify a CRP-based therapeutic window for the combination therapy. Methods This single-center retrospective study included 204 patients who were assigned to the HP + CVVH group (n = 103) or the CVVH group (n = 101). Multivariable logistic regression was used to assess the overall difference in efficacy between the two groups. Restricted cubic splines (RCS) were employed to analyze the nonlinear relationship between treatment efficacy and CRP levels and to identify a CRP-based therapeutic window. Secondary outcomes were analyzed using multivariable logistic regression for categorical variables and generalized linear models for quantitative variables. Results After multivariable adjustment, the incidence of SAP did not differ significantly between the HP + CVVH and CVVH groups (p > 0.05). RCS analysis revealed a significant interaction between treatment group and CRP levels. The conditional odds ratio for SAP (HP + CVVH vs. CVVH) was significantly below 1 only within a specific CRP range: 194.96-296.91 mg/L in the primary analysis and 200.77-285.81 mg/L after propensity score adjustment (p 0.05). Conclusion HP + CVVH showed no overall superiority to CVVH alone in preventing SAP. Nevertheless, secondary outcome analyses demonstrated improved inflammatory control, faster resolution of systemic inflammatory response, reduced intra-abdominal pressure, and better recovery in several resource-related and treatment-related indicators, indicating measurable biological and clinical process benefits. These benefits, however, did not translate into a uniform reduction in SAP. The effect of HP + CVVH on the hard endpoint was conditional, nonlinear, and dependent on baseline inflammatory burden, with significant benefit confined to a specific CRP therapeutic window. Therefore, improvements in secondary endpoints should not be equated with hard-endpoint benefit, and the decision to initiate HP + CVVH should be individualized according to the intensity of the inflammatory response.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。